Craneware reports 9% revenue growth to $205.7m in fiscal 2025

Craneware plc reported strong financial performance for FY2025, with revenue increasing 9% to $205.7 million and Adjusted EBITDA rising 12% to $65.3 million, supported by a net revenue retention rate of 107%. The healthcare software provider strengthened its balance sheet, boosting cash to $55.9 million and reducing bank debt, while also proposing a 10% higher total dividend. Post-period, Craneware secured a new $100 million unsecured revolving credit facility, and management expressed confidence in continued growth acceleration for fiscal year 2026, indicating robust operational momentum and enhanced financial flexibility.

Analysis

Craneware plc (CRW.L) has reported a robust set of fiscal year 2025 results, demonstrating strong operational momentum and financial health. Revenue grew 9% to $205.7 million, underpinned by a 7% increase in annual recurring revenue to $184 million. A key positive indicator is the significant improvement in net revenue retention, which rose to 107% from 98% in the prior year, signaling effective expansion within its existing hospital customer base. Profitability also saw material gains, with adjusted EBITDA increasing 12% to $65.3 million, yielding a healthy margin of 32%, while statutory profit before tax surged 52% to $24 million. The company significantly strengthened its balance sheet by increasing its cash position to $55.9 million and reducing bank debt to $27.7 million. This financial discipline is complemented by a 10% increase in the total dividend to 32 pence per share. Looking forward, management's confidence is supported by a strong start to fiscal 2026 and enhanced financial flexibility from a new $100 million unsecured revolving credit facility, positioning the company for what it anticipates will be accelerated growth.

Key Decisions for Investors

• Investors should view the combination of accelerating revenue growth, margin expansion, and a sharp improvement in net revenue retention to 107% as strong evidence of the company's pricing power and successful cross-selling strategy.
• The strengthening balance sheet, marked by increased cash and reduced debt, coupled with the new $100 million credit facility and a 10% dividend hike, signals both financial stability and capacity for future strategic initiatives or enhanced shareholder returns.
• Given management's guidance for continued growth acceleration in fiscal 2026, market participants should monitor for execution on this outlook, as sustained performance could warrant a re-rating of the stock.
• The external validation for its Trisus product from Microsoft and KLAS underscores the company's competitive positioning in the healthcare AI space, a key long-term growth catalyst to consider.